Orphinic selects promising projects in therapeutics, MedTech, and e-Health, verifies research hypotheses through clinical trials, and partners with large pharmaceutical companies.

Orphinic

Orphinic Scientific S.A. was funded in 2019 as the first Polish biotech portfolio platform creating innovative solutions for orphan diseases and other indications with significant unmet medical needs in the clinical trial phase. 
Orphinic core scientific team consist of experts with over 20 years experience in clinical development processes and their commercialization. The company’s competencies in clinical stage development are further enforced through a collaboration with a large clinical CRO operating in the CEE region. This facilitates access to diverse patient populations and rapid enrollment to clinical trials supporting our projects and significantly shortens the duration of individual phases.
Orphinic currently has 8 projects in the pipeline that range from a preclinical phase to market approval stages in three healthcare segments: therapeutics, medtech and e-health.

⏱ We shorten time to the market due to specialized healthcare centers in CEE and an affiliated CRO. 
🩺 Our team has an exceptional track record in sourcing and exiting high-quality projects. 
🧬 Our portfolio represents clinic-ready assets, with first projects ready to exit in 2023, and a preclinical pipeline for long-term value creation.
💊 We invest in projects with low correlation. Average project risk of c.50% with average returns of c.10x our investment.
📈 Our plan is to IPO at Warsaw Stock Exchange by the end of 2022.
 

Orphinic Scientific

👉 "We will eventually cope with cancer 🦀, the challenge is to maintain cognitive functions 🙇. In an ideal world, medical students 👩‍⚕️ will learn primarily how to communicate with patients🤳 , leaving the diagnosis to the power of artificial intelligence that analyzes medical data in a second 🤖,"  believes Adam Kruszewski, MD,  CEO and co-founder of the biotechnology holding Orphinic Scientific. His essay on medicine of the future was published by the mZdrowie.pl.
📕 https://lnkd.in/d95STW34

The BIO International Convention is the largest and most comprehensive event for biotechnology. Let's meet 🤝

#BIO2024 #BioTech #OneonOne #Partnering

📣 As you already know💡, Orphinic Scientific became a finalist of the "Entrepreneur of the Year of the University of Warsaw" competition in the start-up category three weeks ago 🏆.

👉 "We are a company that helps inventors fulfill their dreams and commercialize new drug therapies. In addition, as a firm from Poland, we entered the world's first league," says Adam Kruszewski, CEO of Orphinic.

🎥 Watch our short video: https://lnkd.in/deeyY3T4.

Orphinic Scientific portfolio company DEBN Sp. z o.o. has announced the start of clinical trials of DEBN, the first medical device that enables simultaneous organ-targeted delivery of antibiotics during prostate biopsy procedures.
This innovation comes at a critical time as new research forecasts that global deaths from prostate cancer will almost double in the next 20 years. 

Read more about it here: https://lnkd.in/gdh_H9WA
#ProstateCancer #MedicalDevice #ClinicalTrials #Innovation

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

Euro

Google Font API

Google Analytics

WordPress

LetsEncrypt

Chair, Supervisory Board

Jaroslaw Leszczyszyn

Project Manager

Michał Krużycki

Jarosław Oleszczuk

Wojciech Tomikowski

Chief M&A Officer & Co-Founder

Chief Scientific Officer & Co-Founder

Adam Kruszewski

Chief Executive Officer & Co-Founder

Artur Plonowski

Chief Medical Officer & Co-Founder

Biopharma Companies

Pharmaceutical Companies With Fewer Than 100 Employees (Top 10K)

Pharmaceutical Companies With Fewer Than 10 Employees

European Union (EU) Pharmaceutical Companies

Orphinic is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1/2.

Warsaw

Mazowieckie

Poland

Europe

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 7, 2024 5:58 PM	339a2919
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	b5413992
crunchbase profile	general	Oct 31, 2024 2:03 AM	d2794a61
li profile	general	Aug 7, 2024 5:58 PM	b03edd45
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	d595fe5c
peers	general	Aug 7, 2024 5:58 PM	e84102d5
news basic	general	Aug 7, 2024 5:58 PM	e8d175a8
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ORPH

COM:ORPHINIC

Orphinic